This website uses cookies. By using our website you consent to all cookies in accordance with our Privacy Policy. Read more - OK, thanks

Back to Suggested Publications

Wednesday 16 March 2016
Pharmacologic management of neuropsychiatric lupus

This week, WAidid suggests the article Pharmacologic management of neuropsychiatric lupus published this year in Expert Review of Clinical Pharmacology.

SUMMARY:
Neuropsychiatric lupus (NPSLE) affects above 50% of patients with systemic lupus erythematosus and may span from mild symptoms to acute devastating life-threatening ones. Owing to the clinical variability, most pharmacological data rely on small, uncontrolled trials and case reports. The mainstay of therapy relies on immune-suppression by glucocorticoids, in adjunction with cyclophosphamide or anti-B-cell therapy, in moderate to severe cases. In selected scenarios (e.g., chorea) intravenous immunoglobulin or plasmapheresis may be effective. Anticoagulation is warranted if anti-phospholipid antibodies are present. In parallel there may be a need for symptomatic treatment such as anti-epileptic or anti-depressive treatments, etc. In the future, more studies addressed to assess pathogenesis and preferred treatments of specific manifestations are needed in order to personalize treatments.

AUTHORS:
Kivity S, Baker B, Arango MT, Chapman J, Shoenfeld Y.